Social Media Ideas for Colossal Biosciences Inc

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger

Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of the public market. Tr...

ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray

While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hop...

Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has up...

Colossal Biosciences says breakthrough means it's a step closer to resurrecting giant moa

The project has faced backlash, but has financial backing from filmmaker Sir Peter Jackson.

City aims to lay foundation for RNAi renaissance with nearly $100M series B

Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further d...

Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering

The aim of the partnership is to provide a platform delivering high-end performance with an optimal cost-of-goods and price-per-dose model to ease scale-up, commercial strategy, an...

Cytomos’ AuraCyt Digital Predictive Cell Analytics Platform Showcased at BIO Conference

Cytomos says its benchtop cell analytics intelligence system combines the compact Celledonia analyzer with the sensors of the AuraCyt modules to transform complex cellular data int...

Circio’s circVec and Tcelltech’s nanoSMAR Technologies Combined to Generate Nextgen In vivo CAR-T and TCR-T Cells

Circio and Tcelltech will combine Circio's circVec circular RNA expression technology with Tcelltech's non-viral, high-cargo capacity nanoSMAR vector platform and evaluate the comb...

Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies

As TSC-101 is advanced toward a pivotal trial, which is expected to begin later this year, Cellares’ manufacturing platform is being evaluated as a scalable and economical path to...

Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push

An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.

Partnership with Oxford Nanopore Technologies will support development of RNA liquid biopsy for cancer early detection

RNA sequencing and nanopore sequencing enabled Eclipse-like full transcriptome analysis to identify novel non-coding RNA biomarkers in extracellular vesicles for early esophageal.....

Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO

Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will s...

<![CDATA[Catalent Announces Expanded Partnership with Nanoscope Therapeutics]]>

Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precisio...

The Blank Bio and PacBio collaboration combines long-read RNA sequencing and AI foundation models to improve biomarker discovery, patient stratification, and precision... The post...

cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara

In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

The focus of the company is SERP-01, an in vivo base editing program targeting AATD developed in China and licensed from YolTech Therapeutics. 

Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE from China’s Metis TechBio

U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.

Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 developmen...

Cancer-focused Parabilis’ upsized $670M IPO breaks new record for biotechs

Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history.

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

Exelixis’ Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review

Exelixis’ next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts suggested that an FDA approval is still on the table.

Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery

Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma.

Roche launches Axelios 1, its eagerly awaited gene sequencing rival to Illumina

Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist’s market share with its own next-gen platform.